Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Absci official news RSS · Indexed industry source record · Source published: Thu Sep 24 2026 12:00:49 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.